Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo

Table 1 Patient, Intervention, Comparator, and Outcome (PICO) criteria concerning Janus kinase (JAK) inhibitors for the treatment of vitiligo

Patient	Intervention (mode of administration)	Intervention (dose and dose frequency studied)	Intervention (duration of therapy)	Comparator	Outcome measures*	Study type
Children and adults with vitiligo	Topical or systemic Janus kinase (JAK) inhibitors	Various doses and frequencies	Within 1 year or longer	Standard therapy	Quality of life	Observational or interventional
					Percentage of repigmentation
					Cosmetic acceptability of repigmentation
					Decreased spreading of the disease
					Lasting repigmentation due to treatment after a 2-year follow-up
					Tolerability or burden of treatment
					Adverse events

*Core outcome set for vitiligo clinical trials obtained from Eleftheriadou et al. [27]

ISSN: 2046-4053